Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5773475

O=C(CCc1cnoc1-c1ccc(C(F)(F)F)cc1)NC1CCN(Cc2ccccc2)C1.O=C(O)C(F)(F)F

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 6/20 0.58
DRD2 P14416 4/20 0.58
SIGMAR1 Q99720 5/20 0.52
HDAC3 O15379 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51
NCOR2 Q9Y618 1/20 0.51
CCR2 P41597 1/20 0.49
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
ATM Q13315 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
BCHE P06276 2/20 0.47
ACHE P22303 2/20 0.47
BACE1 P56817 2/20 0.47
HTR2A P28223 1/20 0.47
TEAD1 P28347 1/20 0.47
S100A4 P26447 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5771823 0.95 SIGMAR1 (0.58) DRD4DRD2SIGMAR1TSHRHTT
Trifluoroacetic Acid SCHEMBL5771830 0.93 DRD2 (0.54) DRD4DRD2SIGMAR1HDAC3HDAC4
SCHEMBL5773476 0.78 DRD2 (0.46) DRD4DRD2SIGMAR1HDAC3HDAC4
Trifluoroacetic Acid SCHEMBL5774584 0.77 MEN1 (0.44) DRD4DRD2HDAC3HDAC4HDAC7
Trifluoroacetic Acid SCHEMBL5774450 0.77 HTT (0.40) SIGMAR1TSHRHTTATMSMN1; SMN2
Trifluoroacetic Acid SCHEMBL5776133 0.77 HTT (0.39) HTTS100A4
Trifluoroacetic Acid SCHEMBL5773674 0.77 OPRM1 (0.47) DRD4DRD2
SCHEMBL5771825 0.76 KCNH2 (0.47) DRD4DRD2SIGMAR1BCHEACHE
SCHEMBL8712569 0.74 DRD4 (1.00) DRD4DRD2HDAC3HDAC4HDAC7
SCHEMBL11576999 0.74 SIGMAR1 (0.65) DRD4DRD2SIGMAR1CCR2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060084690-A1 Isoxazole derivatives MOMOSE YU 2006-04-20 US disclosed
US-7022725-B2 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-04 US disclosed
US-20040048908-A1 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-11 US disclosed
EP-1340749-A1 ISOXAZOLE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084690-A1 Isoxazole derivatives INSR, GPR119, INSRR DRD4 2268/4885DRD2 2788/4885SIGMAR1 653/4885
US-20040048908-A1 Isoxazole derivatives GPR119, INSR, IRS1 DRD4 2538/4885DRD2 2833/4885SIGMAR1 874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.